Sep 2026
A Pilot Clinical Trial of Cetuximab Combined With Tislelizumab as Neoadjuvant Therapy for Locally Advanced Oral Squamous Cell Carcinoma.
Neoadjuvant cetuximab plus tislelizumab plus tislelizumab showed feasible delivery, encouraging antitumor activity, and acceptable safety in patients with locally advanced oral squamous cell carcinoma who were medically unsuitable for conventional cytotoxic chemotherapy.
Wen-Jie Wu, Pu-Gen An, Xiao Hu et al.
· Head and Neck · 0 citations